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Abstract: Background: Chronic kidney disease (CKD) is associated with increased vascular risk. Some studies suggested 
that considering markers of CKD might improve the predictive accuracy of the Framingham risk equation.  
Aim: To evaluate the links between kidney function and risk stratification in patients with primary dyslipidemia.  
Methods: Dyslipidemic patients (n = 156; 83 men) who were non-smokers, did not have diabetes mellitus or evident  
vascular disease and were not on lipid-lowering or antihypertensive agents were recruited. Creatinine clearance (CrCl) 
was estimated using the Cockcroft-Gault equation. Estimated glomerular filtration rate (eGFR) was calculated using the 
Modification of Diet in Renal Disease (MDRD) equation. We estimated vascular risk using the Framingham equation.  
Results: In both men and women, there was a significant negative correlation between estimated Framingham risk   
and both eGFR and CrCl (p < 0.001 for all correlations). When men were divided according to creatinine tertiles, there 
were no significant differences in any parameter between groups. When men were divided according to either eGFR or 
CrCl tertiles, all estimated Framingham risks significantly increased as renal function declined (p<0.001 for all trends). 
When women were divided according to creatinine tertiles, all estimated Framingham risks except for stroke significantly 
increased as creatinine levels increased. When women were divided according to either eGFR or CrCl tertiles, all   
estimated Framingham risks significantly increased as renal function declined.  
Conclusions: Estimated vascular risk increases as renal function declines. The possibility that incorporating kidney   
function in the Framingham equation will improve risk stratification requires further evaluation. 
Key Words: Creatinine, estimated glomerular filtration rate, chronic kidney disease, vascular risk, Framingham risk score.  
INTRODUCTION 
  Primary prevention of vascular disease should be guided 
by the assessment of global risk [1-3]. Patients with higher 
vascular risk should be managed more aggressively [1, 3, 4]. 
A number of risk estimation engines that consider different 
risk factors have been developed [5, 6]. The Framingham 
risk score for subjects without evident vascular disease is 
well established [5]. 
  The Framingham calculation considers the following 
vascular risk factors: age, gender, total cholesterol (TC), 
high density lipoprotein cholesterol (HDL-C), smoking,   
systolic blood pressure (SBP), diastolic blood pressure   
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(DBP), the presence of diabetes mellitus (DM) and left   
ventricular hypertrophy [5]. Limitations of the Framingham 
risk equation include the absence of family history (FaHist) 
of premature vascular disease and age limits [1, 7, 8].   
Furthermore, triglyceride (TG) levels and potentially   
relevant emerging risk factors are not considered [1, 7, 8]. In 
some studies, the assessment of emerging risk factors, such 
as high sensitivity C-reactive protein (hsCRP), added to the 
prognostic accuracy of the Framingham risk equation [9,10]. 
Similarly, chronic kidney disease (CKD) is associated with 
increased vascular risk in the general population [11-14]. 
Some studies suggested that considering markers of CKD 
might improve the predictive accuracy of the Framingham 
equation [15-17]. 
  The aim of the present study was to evaluate the links 
between kidney function and risk stratification (using the 
Framingham equation) in non-smokers with primary dyslipi-
demia and no evident vascular disease or DM. 58    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Tziomalos et al. 
METHODS 
Patient Selection  
  The records of 645 consecutive patients referred to a   
specialist centre for dyslipidemia were assessed [18, 19]. 
Among these patients, we identified 234 patients (144 men) 
without overt vascular disease or DM. In order to create   
an even more homogeneous patient group, the following 
exclusion criteria were also applied [18, 19]: 
1) Treatment with any lipid lowering or antihypertensive 
agent during the previous 4 months. 
2) Those with fasting serum glucose concentration > 5.0 
mmol/l required a normal oral glucose tolerance test in 
order to be included in the survey. 
3) Abnormal liver function tests: Reference ranges were: 
aspartate aminotransferase = 5 - 40 u/l; alanine 
aminotransferase = 5 - 40 u/l; gamma-glutamyl trans-
ferase = 10 - 48 u/l; alkaline phosphatase = 35 - 130 u/l; 
albumin = 35 - 55 g/l; bilirubin = 3 - 17 μmol/l (values up 
to 25 μmol/l were allowed provided all other liver   
function tests were normal). 
4)  Abnormal renal function: Reference ranges were: urea = 
3.0 - 6.5 mmol/l (values up to 7.5 mmol/l were allowed 
for those above the age of 70 years); creatinine = 60 - 
120 μmol/l; sodium = 135 - 145 mmol/l; potassium = 3.5 
- 5.0 mmol/l. 
5)  Abnormal thyroid function tests: Reference ranges were: 
thyroid stimulating hormone = 0.5 - 4.7 mU/l; free   
thyroxine = 10 - 25 pmol/l. 
6)  Declared or determined history of alcohol or drug abuse. 
For alcohol consumption, the limits were set at 21 and 14 
units/week for men and women, respectively. 
7) Psychiatric conditions, whether involving medication or 
not. 
8) Chronic inflammatory disease (e.g. rheumatoid arthritis, 
Crohn’s disease, ulcerative colitis, collagen diseases)   
or cancer [since an acute phase response may influence 
several variables (e.g. HDL-C)] [20-23]. 
9) Treatment with retinoic acid derivatives, tamoxifen,   
androgens, oestrogens (hormone replacement therapy or 
oral contraceptives), progestins, fish oils or ciclosporin 
since these drugs may exert effects on lipids [24-28]. 
10) Current or recent (4-month) pregnancy. 
11) Current smokers or those who quit had quit for less   
than 6 months before sampling. A 6-month period was 
selected to allow time for reversal of measured variables 
within a practical time frame. 
Clinical and Laboratory Investigations 
  Collection of samples: All samples were collected in the 
morning after fasting for a minimum of 12 h with water only 
allowed. 
  Lipid profile: Serum TC, HDL-C and TG levels were 
assayed by standard enzymatic methods (Boehringer Mann-
heim, Sussex, England) adapted for the Hitachi 911 analyser 
(HDL-C was measured after precipitating apolipoprotein B  
 
using a phosphotungstate procedure).
  Serum low density 
lipoprotein cholesterol (LDL-C) levels were calculated by 
the Friedewald formula. Patients with serum TG levels > 4.5 
mmol/l, in whom LDL-C cannot be determined by the above 
formula, are not included in the analysis. 
  Liver and renal function profiles and serum glucose con-
centration were all determined by standard methods used in 
our department. 
  Creatinine clearance (CrCl) was estimated using the 
Cockcroft-Gault equation: CrCl (ml/min) = [140 – age   
(in years)] x [weight (in kg)] x 0.85 (if female) / [72 x serum 
creatinine (in mg/dl)] [29]. Estimated glomerular filtration 
rate (eGFR) was calculated using the Modification of Diet in 
Renal Disease (MDRD) equation: eGFR (ml/min/1.73 m
2) = 
186 x [serum creatinine (in mg/dl)]
(-1.154) x [age (in years)] 
(-0.203) x 0.742 (if female) x 1.210 (if black) [30]. 
  The Department of Clinical Biochemistry, Royal Free 
Hospital participates in several quality assurance programs 
and has full Clinical Pathology Accreditation (CPA). 
Calculation of Vascular Risk Using the Framingham 
Equation [www.bhsoc.org] 
  The Framingham risk engine can only be used to   
calculate vascular risk in the absence of cardiovascular   
disease (CVD). The following variables are considered:   
age, gender, SBP and DBP, serum TC and HDL-C levels, 
smoking status and the presence/absence of DM or left   
ventricular hypertrophy based on electrocardiographic   
criteria [5]. The equation estimates the 10-year risk for   
coronary heart disease (CHD), stroke and overall CVD based 
on either SBP (SBP-CHD, SBP-stroke and SBP-CVD,   
respectively) or DBP (DBP-CHD, DBP-stroke and DBP-
CVD, respectively). We also estimated CVD risk taking   
a FaHist of premature vascular disease (any event before   
the age of 60 years) into consideration (termed SBP-
CVD+FaHist and DBP-CVD+FaHist, respectively). A   
positive FaHist was considered to add 50% to the overall 
risk. 
  The Framingham equation has age limits (32 to 74 
years). To increase the number of patients, men aged 24-31 
years were entered as 32 years old and those aged 75-76 
years were entered as 74 years old. Similarly, women aged 
27-31 years were entered as 32 and those aged 75-78 years 
were entered as 74 years old. 
Statistical Analysis 
  All data were analyzed using the statistical package SPSS 
(version 12.0; SPSS Inc., Chicago, IL). Continuous values 
are expressed as median and range. Correlations between 
variables were assessed using Spearman Rank correlation. 
The Kruskal-Wallis test was used to assess the trend of   
variables divided according to creatinine, eGFR or CrCl   
tertiles. The chi-square test was used to compare the agree-
ment between eGFR and CrCl in classifying patients in terti-
les of renal function. Because we assessed the correlation 
between indices of renal function (creatinine, eGFR   
and CrCl) and 22 other parameters, a 2-tailed p < 0.031 was 
considered significant [31]. In all other analyses, a 2-tailed  
p < 0.05 was considered significant. Kidney Function and Estimated Vascular Risk  The Open Cardiovascular Medicine Journal, 2009, Volume 3    59 
RESULTS 
  The clinical characteristics of the 156 patients (83 men) 
enrolled in this survey are listed in Table 1. Estimated risk 
for CHD, stroke and CVD based on SBP and DBP are shown 
in Table 2. 
  Significant correlations between the indices of renal 
function (creatinine, eGFR and CrCl) and other parameters 
are shown in Tables 3 and 4. In men, there was a significant 
positive correlation between creatinine levels and SBP-CHD, 
SBP-CVD, DBP-CHD and DBP-CVD (Table 3). In women, 
creatinine levels correlated significantly with all estimated 
risks (Table 4). In both men and women, there was a signifi-
cant negative correlation between all estimated risks and 
both eGFR and CrCl (p < 0.001 for all correlations; Tables 3 
and 4). 
  When men were divided according to creatinine tertiles, 
there were no differences in any parameter between groups. 
When men were divided according to either eGFR or CrCl 
tertiles, all estimated risks increased significantly as renal 
Table 1.  Clinical Characteristics of the Study Population 
  Men 
(n = 83) 
Women 
(n = 73) 
Age (years)  49 (24-76)  55 (27-78) 
Weight (kg)  81.2 (61.1-119.0)  65.3 (45.7-96.0) 
Systolic blood pressure (mmHg)  130 (85-170)  135 (100-185) 
Diastolic blood pressure (mmHg)  80 (60-100)  80 (70-115) 
Lipid profile 
TC (mmol/l) 
LDL-C (mmol/l) 
HDL-C (mmol/l) 
TG (mmol/l) 
TC/HDL-C  
LDL-C/HDL-C 
Lipoprotein a (g/l) 
 
7.1 (4.5-12.2) 
5.0 (2.4-9.3) 
(0.6-2.1) 
2.2 (0.7-7.4) 
6.3 (3.6-14.2) 
4.3 (2.4-10.2) 
0.25 (0.05-2.10) 
 
7.6 (4.5-11.7) 
5.4 (2.7-9.7) 
1.4 (0.6-2.6) 
1.6 (0.5-4.8) 
5.6 (2.7-12.3) 
4.0 (1.4-8.9) 
0.34 (0.05-1.54) 
Fibrinogen (g/l)  3.05 (1.44-5.47)  3.51 (2.11-6.29) 
Glucose (mmol/l)  4.8 (3.6-5.6)  4.7 (3.3-6.1) 
Urate (mmol/l)  0.38 (0.21-0.81)  0.28 (0.17-0.51) 
Renal function 
Creatinine (μmol/l) 
eGFR (MDRD) (ml/min/1.73 m
2) 
Creatinine clearance (CG) (ml/min) 
 
93 (72-112) 
80 (62-115) 
101 (58-153) 
 
74 (51-120) 
76 (42-120) 
82 (30-148) 
TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; eGFR, estimated glomerular filtration rate; MDRD, 
modification of diet in renal disease equation. CG, cockcroft-gault equation.  
 
Table 2.  Estimated Vascular Risk of the Study Population 
  Men 
(n = 83) 
Women 
(n = 73) 
SBP-CHD  11.2 (0.7-41.4)  9.1 (0.0-22.1) 
SBP-stroke  1.1 (0.1-8.5)  1.4 (0.1-9.7) 
SBP-CVD  12.4 (0.8-49.3)  10.6 (0.1-31.8) 
DBP-CHD  10.7 (0.5-40.0)  9.3 (0.0-23.1) 
DBP-stroke  0.9 (0.0-8.7)  1.3 (0.0-8.3) 
DBP-CVD  11.7 (0.5-45.4)  11.0 (0.0-31.4) 
SBP-CVD + FaHist  14.6 (1.2-73.9)  12.0 (0.1-47.7) 
DBP-CVD + FaHist  14.3 (0.7-68.1)  13.5 (0.0-47.1) 
CHD, coronary heart disease; CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; FaHist, family history; SBP-CHD, estimated CHD risk 
based on SBP; SBP-stroke, estimated stroke risk based on SBP; SBP-CVD, estimated CVD risk based on SBP; DBP-CHD, estimated CHD risk based on DBP; DBP-stroke, esti-
mated stroke risk based on DBP; DBP-CVD, estimated CVD risk based on DBP; SBP-CVD + FaHist, estimated CVD risk based on SBP and the presence of FaHist; DBP-CVD + 
FaHist, estimated CVD risk based on DBP and the presence of FaHist. 60    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Tziomalos et al. 
function declined (p<0.001 for all trends; Tables 5 and 6). It 
should be noted that there was significant disagreement in 
the classification of men in tertiles according to eGFR or 
CrCl. Thus, among men in the lowest, middle and higher 
eGFR tertile, only 46, 29 and 70%, respectively, were also  
in the lowest, middle and higher CrCl tertile, respectively   
(p < 0.001). 
  When women were divided according to creatinine   
tertiles, all estimated risks except for stroke significantly 
increased as creatinine levels increased (Table 7). When 
women were divided according to either eGFR or CrCl   
tertiles, all estimated risks significantly increased as renal 
function declined (Tables 8 and 9). There was significant 
disagreement in the classification of women in tertiles 
Table 3.  Significant Correlations Between Markers of Renal Function and Other Parameters in Men (n = 83). DUE to Multiple 
Correlations, a p value < 0.031 is Considered Significant 
Correlations between serum creatinine levels and other parameters 
Parameter r  P 
TC 0.252  0.022 
LDL-C 0.249  0.023 
TC/HDL-C ratio  0.256  0.02 
LDL-C/HDL-C ratio  0.291  0.008 
SBP-CHD 0.289  0.008 
SBP-CVD 0.259  0.018 
DBP-CHD 0.292  0.007 
DBP-CVD 0.268  0.014 
Correlations between eGFR (MDRD) and other parameters 
Parameter r  P 
Age -0.544  <0.001 
SBP-CHD -0.605  <0.001 
SBP-stroke -0.456  <0.001 
SBP-CVD -0.588  <0.001 
DBP-CHD -0.620  <0.001 
DBP-stroke -0.520  <0.001 
DBP-CVD -0.607  <0.001 
SBP-CVD + FaHist  -0.501  <0.001 
DBP-CVD + FaHist  -0.533  <0.001 
Correlations between creatinine clearance (CG) and other parameters 
Parameter r  P 
Age -0.807  <0.001 
Weight 0.599 <0.001 
HDL-C -0.283  0.010 
SBP-CHD -0.697  <0.001 
SBP-stroke -0.703  <0.001 
SBP-CVD -0.708  <0.001 
DBP-CHD -0.714  <0.001 
DBP-stroke -0.763  <0.001 
DBP-CVD -0.727  <0.001 
SBP-CVD + FaHist  -0.632  <0.001 
DBP-CVD + FaHist  -0.667  <0.001 
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Table 4.  Significant Correlations Between Markers of Renal Function and Other Parameters in Women (n = 73). Due to Multiple 
Correlations, a p value < 0.031 is Considered Significant 
Correlations between serum creatinine levels and other parameters 
Parameter r  p 
Age 0.330  0.004 
Triglycerides 0.273  0.019 
Glucose 0.258  0.029 
Urate 0.408  0.001 
SBP-CHD 0.361  0.002 
SBP-stroke 0.317  0.006 
SBP-CVD 0.349  0.002 
DBP-CHD 0.348  0.003 
DBP-stroke 0.344  0.003 
DBP-CVD 0.348  0.003 
SBP-CVD+ FaHist  0.360  0.002 
DBP-CVD+ FaHist  0.370  0.001 
Correlations between eGFR (MDRD) and other parameters 
Parameter r  p 
Age -0.535  <0.001 
Fibrinogen -0.298  0.011 
Glucose -0.342  0.003 
Triglycerides -0.308  0.008 
Urate -0.435  <0.001 
SBP-CHD -0.510  <0.001 
SBP-stroke -0.502  <0.001 
SBP-CVD -0.511  <0.001 
DBP-CHD -0.499  <0.001 
DBP-stroke -0.544  <0.001 
DBP-CVD -0.515  <0.001 
SBP-CVD+ FaHist  -0.525  <0.001 
DBP-CVD+ FaHist  -0.538  <0.001 
Correlations between creatinine clearance (CG) and other parameters 
Parameter r  p 
Age -0.685  <0.001 
Weight 0.318 0.006 
Fibrinogen -0.275  0.019 
Glucose -0.303  0.01 
SBP-CHD -0.556  <0.001 
SBP-stroke -0.628  <0.001 
SBP-CVD -0.582  <0.001 
DBP-CHD -0.531  <0.001 
DBP-stroke -0.649  <0.001 62    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Tziomalos et al. 
Table 4 contd…. 
Correlations between creatinine clearance (CG) and other parameters 
Parameter r  p 
DBP-CVD -0.569  <0.001 
SBP-CVD+ FaHist  -0.607  <0.001 
DBP-CVD+ FaHist  -0.612  <0.001 
For abbreviations, see Table 2. 
 
Table 5.  Significant Differences Between Groups when men where Divided According to Estimated Glomerular Filtration Rate 
Tertiles (Modification of Diet in Renal Disease Equation) 
  Estimated Glomerular Filtration Rate Tertiles 
(ml/min/1.73 m
2) 
p 
for Trend 
  < 75 
(n = 28) 
75-86 
(n = 28) 
> 86 
(n = 27) 
 
LDL-C (mmol/l)  5.2 (3.3-7.7)  4.5 (2.4-6.9)  4.9 (2.6-9.3)  0.028 
TC/HDL-C  7.2 (4.6-10.9)  5.5 (3.6-9.0)  6.4 (4.6-14.2)  0.002 
LDL-C/HDL-C  5.2 (3.1-7.7)  3.5 (2.4-6.5)  4.3 (2.8-10.2)  <0.001 
Age (years)  52.5 (43-76)  51.5 (25-67)  36 (24-70)  <0.001 
SBP-CHD  17.2 (6.9-41.4)  10.2 (1.3-22.8)  5.4 (0.7-25.9)  <0.001 
SBP-stroke  1.5 (0.2-8.5)  1.3 (0.1-4.4)  0.4 (0.1-7.7)  <0.001 
SBP-CVD  18.2 (7.1-49.3)  11.6 (1.4-26.0)  5.7 (0.8-32.5)  <0.001 
DBP-CHD  16.3 (7.7-40.0)  10.0 (0.7-22.8)  5.0 (0.5-24.6)  <0.001 
DBP-stroke  1.2 (0.4-8.7)  1.2 (0.0-3.9)  0.2 (0.0-4.7)  <0.001 
DBP-CVD  17.8 (8.5-45.4)  10.8 (0.7-25.8)  5.2 (0.5-29.3)  <0.001 
SBP-CVD+ FaHist  19.8 (7.1-73.9)  14.6 (2.1-35.5)  7.9 (1.2-32.5)  <0.001 
DBP-CVD+ FaHist  19.2 (8.8-68.1)  15.4 (1.0-32.8)  7.3 (0.7-29.3)  <0.001 
For abbreviations, see Tables 1 and 2. 
 
Table 6.  Significant Differences Between Groups when men where Divided According to Creatinine Clearance (Cockcroft-Gault 
Equation) 
  Creatinine Clearance Tertiles 
(ml/min) 
P 
for Trend 
 <  90 
(n = 28) 
90-109 
(n = 28) 
> 109 
(n = 27) 
 
TG (mmol/l)  1.6 (0.7-3.3)  2.5 (0.8-7.4)  2.5 (0.9-4.8)  0.02 
HDL-C (mmol/l)  1.2 (0.7-2.1)  1.1 (0.8-1.9)  1.0 (0.6-1.4)  0.042 
Weight (kg)  72.9 (61.1-83.0)  87.1 (62.0-96.6)  84.5 (72.2-119.0)  <0.001 
Age (years)  58.5 (44-76)  49 (31-64)  34 (24-51)  <0.001 
SBP-CHD  16.1 (7.9-41.4)  12.1 (1.6-24.8)  5.2 (0.7-13.2)  <0.001 
SBP-stroke  2.2 (0.5-8.5)  1.1 (0.2-7.7)  0.3 (0.1-1.5)  <0.001 
SBP-CVD  18.4 (8.4-49.3)  13.4 (2.8-32.5)  5.6 (0.8-14.6)  <0.001 
DBP-CHD  16.5 (7.2-40.0)  12.3 (1.2-21.2)  5.0 (0.5-12.9)  <0.001 
DBP-stroke  2.3 (0.5-8.7)  0.9 (0.1-4.2)  0.2 (0.0-1.2)  <0.001 
DBP-CVD  18.3 (8.5-45.4)  13.6 (1.3-25.2)  5.2 (0.5-13.8)  <0.001 
SBP-CVD+FaHist  19.4 (10.8-73.9)  16.7 (4.2-36.9)  7.6 (1.2-20.7)  <0.001 
DBP-CVD+FaHist  19.7 (8.5-68.1)  16.3 (1.9-33.3)  6.4 (0.7-17.8)  <0.001 
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Table 7.  Significant Differences Between Groups when Women where Divided According to Serum Creatinine Tertiles 
Parameter  Serum Creatinine Tertiles  
(μmol/l) 
P 
for Trend 
   67 
(n = 24) 
68-79 
(n = 24) 
 80 
(n = 25) 
 
DBP (mmHg)  80 (70-115)  85 (70-110)  80 (70-105)  0.041 
TC (mmol/l)  7.6 (4.9-10.1)  7.1 (4.5-11.7)  8.0 (6.0-10.1)  0.023 
TG (mmol/l)  1.2 (0.5-3.6)  1.7 (0.6-4.8)  1.8 (0.6-3.7)  0.044 
LDL-C (mmol/l)  5.7 (2.7-8.4)  4.6 (2.7-9.7)  5.9 (3.9-7.8)  0.028 
Urate (mmol/l)  0.24 (0.17-0.33)  0.30 (0.21-0.50)  0.32 (0.19-0.51)  0.006 
SBP-CHD  4.8 (0.2-22.1)  6.4 (0.0-18.3)  11.2 (1.0-20.8)  0.015 
SBP-CVD  6.3 (0.3-31.8)  9.2 (0.1-24.8)  13.3 (1.4-24.1)  0.03 
DBP-CHD  4.9 (0.1-23.1)  8.6 (0.0-22.4)  12.3 (0.9-22.8)  0.022 
DBP-CVD  6.3 (0.1-31.4)  10.3 (0.0-24.2)  14.2 (1.2-25.8)  0.029 
SBP-CVD+FaHist  8.1 (0.3-47.7)  9.6 (0.1-24.8)  18.3 (2.1-36.1)  0.013 
DBP-CVD+FaHist  8.0 (0.1-47.1)  11.0 (0.0-26.4)  18.3 (1.8-27.0)  0.009 
For abbreviations, see Tables 1 and 2. 
 
Table 8.  Significant Differences Between Groups when Women where Divided According to Estimated Glomerular Filtration Rate 
Tertiles (Modification of Diet in Renal Disease Equation) 
  Estimated Glomerular Filtration Rate Tertiles 
(ml/min/1.73 m
2) 
p 
for Trend 
 <  69 
(n = 24) 
69-83 
(n = 25) 
> 83 
(n = 24) 
 
DBP (mmHg)  82 (70-105)  85 (70-115)  80 (70-90)  0.005 
TG (mmol/l)  1.9 (0.9-3.7)  1.7 (0.6-4.8)  1.2 (0.5-3.6)  0.012 
Fibrinogen (g/l)  3.64 (2.54-5.76)  3.58 (2.32-5.16)  3.15 (2.11-6.29)  0.028 
Glucose(mmol/l)  4.8 (4.2-5.6)  4.7 (3.7-6.1)  4.4 (3.3-6.0)  0.032 
Urate (mmol/l)  0.32 (0.19-0.51)  0.30 (0.21-0.50)  0.25 (0.17-0.33)  0.001 
Age (years)  61 (40-72)  55 (38-78)  48 (27-67)  <0.001 
SBP-CHD  12.1 (1.0-20.8)  8.6 (1.1-22.1)  3.6 (0.0-18.5)  <0.001 
SBP-stroke  2.2 (0.4-7.8)  1.5 (0.2-9.7)  0.5 (0.1-6.3)  0.001 
SBP-CVD  14.7 (1.4-24.1)  10.0 (1.3-31.8)  4.6 (0.1-19.5)  <0.001 
DBP-CHD  12.5 (0.9-22.8)  9.8 (1.2-23.1)  3.4 (0.0-19.2)  <0.001 
DBP-stroke  2.0 (0.3-5.1)  1.6 (0.2-8.3)  0.6 (0.0-2.9)  <0.001 
DBP-CVD  14.8 (1.2-25.8)  11.4 (1.4-31.4)  4.1 (0.0-20.0)  <0.001 
SBP-CVD+FaHist  20.2 (2.1-36.1)  10.8 (1.9-47.7)  5.2 (0.1-25.6)  <0.001 
DBP-CVD+FaHist  18.4 (1.8-27.0)  12.8 (1.9-47.1)  4.1 (0.0-24.0)  <0.001 
For abbreviations, see Tables 1 and 2.  
according to eGFR or CrCl. Thus, among women in the   
lowest, middle and higher eGFR tertile, only 71, 44 and 
67%, respectively, were also in the lowest, middle and 
higher CrCl tertile, respectively (p < 0.001). 
DISCUSSION 
  CKD is defined as the presence of either eGFR < 60 
ml/min/1.73m
2  or
  persistent albuminuria [30]. The preva-
lence of CKD is rising due to the progressive aging of the 64    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Tziomalos et al. 
population and the increasing number of patients with type 2 
DM [32-36]. It was reported that approximately 13.1% of the 
US adult population has CKD [37]. The prevalence of CKD 
in the UK ranges between 5.8 and 12.0% [38,39]. In both 
countries, CKD is more frequent in women than in men [37, 
39]. 
  Several studies showed that impaired renal function is 
associated with increased vascular mortality in the general 
population [11-14], in patients with stable CHD [40-42], 
acute coronary syndromes (ACS) [43, 44], stroke [45] or 
peripheral arterial disease (PAD) [46]. CKD is also a risk 
factor for stroke in the general population [47] and in pa-
tients with CHD [48] although others reported an association 
only with hemorrhagic stroke [49]. CKD is associated with 
increased risk for PAD [50] and renal artery stenosis in the 
general population [51] and correlates with ankle-brachial 
index (ABI) in patients with PAD [52]. Both established and 
emerging risk factors are implicated in the increased vascular 
morbidity and mortality in CKD [53]. 
  In our study, estimated vascular risk significantly in-
creased as kidney function deteriorated. In previous reports, 
the Framingham risk score was higher in patients with CKD 
than in those with normal kidney function [54]. In addition, 
the Framingham model appears to underestimate vascular 
risk in patients with CKD [55]. In contrast, an analysis of the 
Atherosclerosis Risk in the Communities (ARIC) study 
showed that accounting for CKD did not improve discrimi-
nation of the Framingham equation for vascular events [17]. 
In the same study, considering renal function improved dis-
crimination for total mortality in white men but not in white 
women [17]. 
  The MDRD equation is the proposed method for eGFR 
assessment in clinical practice [30]. It is currently recom-
mended that serum creatinine levels should not be used as 
the sole means to assess kidney function [33]. However, the 
MDRD equation was developed in patients with CKD and 
appears to be less accurate in patients with normal kidney 
function or moderately reduced eGFR [30,56,57]. The Cock-
croft-Gault equation also misclassified approximately 30% 
of subjects in population studies [58]. Significant differences 
in classification regarding renal function comparing MDRD 
and Cockcroft-Gault equations were also seen in the present 
study. Other indices of kidney function might also be useful. 
Cystatin C levels might reflect GFR more accurately than 
creatinine [59]. Elevated cystatin C levels were associated 
with vascular events in elderly subjects [60] and in patients 
with established CHD [61]. However, cystatin C levels also 
show variations depending on age, gender, body weight, 
smoking and presence of inflammation [62]. 
  We estimated vascular risk using the Framingham risk 
equation. Some studies performed in the UK showed that the 
Framingham engine accurately predicts vascular events [63] 
although others reported an overestimation of CHD risk with 
this model [64-66]. A meta-analysis showed a considerable 
variation in the predictive value of the Framingham risk 
score in different populations [67]. It appears to overestimate 
risk in low risk populations and to underestimate risk in high 
risk populations [67]. The Prospective Cardiovascular Mun-
ster (PROCAM) score is also used to estimate vascular risk 
[6]. This score considers all risk factors of the Framingham 
equation but replaces LDL-C for TC levels and includes TG 
levels and FaHist of CHD [6]. Elevated TG levels appear to 
be associated with increased vascular risk [68]. Studies in the 
UK showed that PROCAM and Framingham models have 
similar predictive values [65, 66]. In contrast, we reported 
that, in dyslipidemic patients without established vascular 
Table  9.  Significant Differences Between Groups when Women where Divided According to Creatinine Clearance Tertiles   
(Cockcroft-Gault Equation) 
  Creatinine Clearance Tertiles 
(ml/min) 
p 
for Trend 
 <  72 
(n = 24) 
72-89 
(n = 25) 
> 90 
(n = 24) 
 
Fibrinogen (g/l)  395 (234-576)  348 (227-629)  335 (211-446)  0.039 
Glucose (mmol/l)  4.7 (3.9-6.1)  4.8 (3.7-6.0)  4.4 (3.3-5.6)  0.024 
Weight (kg)  61.9 (45.7-79.6)  66.9 (46.3-84.8)  68.7 (53.6-96.0)  0.027 
Age (years)  65 (40-78)  54 (38-68)  43 (27-71)  <0.001 
SBP-CHD  11.8 (1.0-20.8)  9.2 (1.1-22.1)  3.8 (0.0-18.5)  <0.001 
SBP-stroke  2.5 (0.4-8.7)  1.2 (0.2-9.7)  0.4 (0.1-3.5)  0.001 
SBP-CVD  15.1 (1.4-24.8)  10.6 (1.3-31.8)  4.6 (0.1-19.5)  <0.001 
DBP-CHD  12.2 (0.9-22.8)  9.4 (1.2-23.1)  3.8 (0.0-19.2)  0.001 
DBP-stroke  2.9 (0.3-6.1)  1.2 (0.2-8.3)  0.4 (0.0-7.2)  <0.001 
DBP-CVD  16.7 (1.2-25.8)  11.4 (1.4-31.4)  4.4 (0.0-20.0)  <0.001 
SBP-CVD+ FaHist  19.1 (2.1-36.1)  12.9 (1.9-47.7)  4.9 (0.1-25.6)  <0.001 
DBP-CVD+ FaHist  18.4 (1.8-27.0)  14.3 (1.9-47.1)  4.5 (0.0-24.0)  <0.001 
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disease, the Framingham risk score predicted higher risk 
than PROCAM [69]. We did not use the PROCAM calcula-
tion in this study due to its narrow age limits [6]. 
  It is of interest that statins appear to prevent the decline 
of renal function in high risk patients without established 
vascular disease and in patients with CVD [40, 41, 70-78]. A 
number of small studies also reported that statins might re-
duce albuminuria [79, 80]. Other lipid profile modifying 
agents, including ezetimibe and omega-3 fatty acids, might 
also “protect” kidney function [81-86]. In contrast, fibrates 
appear to raise serum creatinine levels [87-94]. It was   
suggested that the fibrates-induced rise in creatinine level is 
due to increased production of creatinine and does not reflect 
a true decline of kidney function [91, 93, 95]. In addition, 
fibrates appear to reduce microalbuminuria in diabetic   
patients [96, 97]. 
  Subgroup analyses of randomized controlled trials in 
high risk patients without established vascular disease and in 
patients with CHD showed that statins reduce vascular risk 
in patients with CKD [42, 98-101]. The ongoing Study of 
Heart and Renal Protection (SHARP) will assess the effects 
of the simvastatin plus ezetimibe combination treatment in 
patients with CKD but without established CHD [102]. In 
the Veterans’ Affairs High-Density Lipoprotein Intervention 
Trial (VA-HIT), gemfibrozil reduced vascular events in   
patients with CKD and established CHD [103]. However, 
there was an increased risk of sustained increase in creatinine 
levels in the gemfibrozil group [103]. 
  Uric acid levels have not been consistent predictors of 
vascular risk [40,104,105]. Some evidence identified a rela-
tionship only in women [105]. Therefore it is of interest that 
in the present study uric acid levels showed a significant 
trend in relation to serum creatinine levels and eGFR only in 
women. 
  A limitation of our study is that we did not evaluate the 
presence of albuminuria, another diagnostic criterion for 
CKD [30] that is also associated with increased vascular risk 
[106-108]. Evaluation of both eGFR and albuminuria is   
currently recommended for the detection of CKD [30] since 
patients with CKD might only have a low eGFR or isolated 
albuminuria [109-111]. In addition, albuminuria and eGFR 
appear to predict vascular disease independently of each 
other [110]. Albuminuria predicted vascular events in hyper-
tensive patients independently of the Framingham risk score 
[112]. It also appears that considering albuminuria might 
improve the predictive accuracy of the Framingham risk 
equation [15,16]. However, the Framingham Heart study 
reported that only reduced eGFR predicted all cause mortal-
ity whereas microalbuminuria did not [111]. A “statistical” 
disadvantage is that many of the variables that differed   
between the tertiles of renal function are actually included 
(directly or indirectly) in the Framingham equation. 
  An advantage of our study is the homogeneous nature of 
the population. None of the participants had DM or overt 
CVD, none were smokers and they were not taking any lipid 
lowering or antihypertensive drugs. 
  In conclusion, estimated vascular risk (using the 
Framingham equation) progressively increases as renal   
function declines. The possibility that incorporating kidney 
function in the Framingham predictive equation will improve 
risk stratification requires further work. 
ABBREVIATIONS 
ABI =  Ankle-brachial  index 
ACS =  Acute  coronary  syndromes 
ARIC  =  Atherosclerosis risk in the communities 
CHD  =  Coronary heart disease 
CKD  =  Chronic kidney disease 
CrCl =  Creatinine  clearance 
CVD =  Cardiovascular  disease 
DBP  =  Diastolic blood pressure 
DM =  Diabetes  mellitus 
eGFR  =  Estimated glomerular filtration rate 
FaHist =  Family  history 
HDL-C  =  High density lipoprotein cholesterol 
hsCRP  =  High sensitivity C-reactive protein 
LDL-C  =  Low density lipoprotein cholesterol 
MDRD  =  Modification of diet in renal disease 
PAD  =  Peripheral arterial disease 
PROCAM  =  Prospective cardiovascular munster 
SBP  =  Systolic blood pressure  
SHARP  =  Study of heart and renal protection 
TC =  Total  cholesterol 
VA-HIT  = Veterans’ affairs high-density lipoprotein 
intervention trial 
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